Search Results - "Shaib, W L"

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours by Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L

“…Background: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and…”
Get full text

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Get full text

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Get full text

721PEfficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications by Droz Dit Busset, M, Braun, S, El-Rayes, B, Harris, W P, Damjanov, N, Masi, G, Rimassa, L, Bhoori, S, Niger, M, Personeni, N, Braiteh, F, Lonardi, S, Engelhardt, M, Saulay, M, Schwartz, B, Shaib, W L, Mazzaferro, V, Papadopoulos, K P

“…Abstract Background FGFR2 gene aberrations (GA) include fusions and mutations/amplifications, with an estimated prevalence of approximately 15% and 5% in iCCA,…”
Get full text

1221PSites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M A, Shabto, J M, Martini, D J, Liu, Y, Lewis, C, Collins, H H, Akce, M, Kissick, H, Carthon, B C, Shaib, W L, Alese, O B, Steuer, C E, Wu, C, Lawson, D H, Kudchadkar, R, Master, V, El-Rayes, B, Ramalingam, S S, Owonikoko, T K, Harvey, R D

Get full text

133PSarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M A, Martini, D J, Shabto, J M, Liu, Y, Khan, A I, Williams, M A, Lewis, C, Collins, H H, Kissick, H, Carthon, B C, Akce, M, Shaib, W L, Alese, O B, Lawson, D H, Kudchadkar, R, El-Rayes, B, Ramalingam, S S, Owonikoko, T K, Harvey, R D, Master, V A

Get full text

Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma by Zakka, Katerina, Jiang, Renjian, Alese, Olatunji B, Shaib, Walid L, Wu, Christina, Wedd, Joel P, Sellers, Marty T, Behera, Madhusmita, El-Rayes, Bassel F, Akce, Mehmet

“…HCC variants are rare primary hepatic tumors. The aim of this study is to compare clinical characteristics and outcomes of HCC variants with pure HCC. Patients…”
Get full text